In a nutshell This study evaluated the safety and effectiveness of the Kd regimen (carfilzomib, dexamethasone) for patients with newly diagnosed multiple myeloma. This study concluded that this regimen was effective for these patients, with mild side effects. Some background Multiple myeloma (MM) is a type of cancer of the bone marrow that...
Read More
In a nutshell This study is evaluating the effectiveness of melphalan (Alkeran) alone compared to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) in patients with multiple myeloma before a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have complete disappearance of all signs of...
Read More
In a nutshell This study evaluated the safety and effectiveness of ixazomib (Ninlaro) given after a stem cell transplant for patients with multiple myeloma (MM). This study concluded that ixazomib maintenance therapy is effective for these patients, with manageable side effects. Some background Multiple myeloma is a type of cancer of the bone marrow...
Read MoreIn a nutshell The study will investigate the effects of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone (Decadron) in multiple myeloma (MM). The main outcome that will be measured will be the percentage of patients who have no signs or symptoms of MM after treatment (completed response). This study is recruiting in Georgia, Unites...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...
Read MoreIn a nutshell This study will investigate the effectiveness of daratumumab (Darzalex) added to VR-d regime [bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Decadron)] versus VR-d alone in untreated multiple myeloma (MM). The development of minimal residual disease (MRD; a very small number of cancer cells remaining after treatment)...
Read More
In a nutshell This study aimed to investigate the use of newer agents and the risk of infections in patients with multiple myeloma. This study concluded that there is a high risk of these patients developing at least one infection during treatment. Some background Infections are a major cause of illness and death in patients with multiple...
Read More
In a nutshell This study aimed to investigate the combination D-VCd containing daratumumab (Darzalex), bortezomib (Velcade), cyclophosphamide (Cytoxan), and dexamethasone (Decadron) in patients with multiple myeloma. This study concluded that this combination was safe and effective for these patients. Some background...
Read More
In a nutshell This study evaluated the effectiveness of several treatment combinations for patients with multiple myeloma (MM) who were not eligible for a stem cell transplant (SCT). This study found that DaraVMP and VMPT were the most effective treatments for these patients. Some background MM is a type of cancer of the bone marrow that can lead...
Read More
In a nutshell This study investigated the safety and effectiveness of a new chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study found that this cell therapy was effective, but it had significant side effects. Some background MM is a type of cancer of the...
Read More
In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...
Read MoreIn a nutshell This study will investigate the effectiveness of a new combination of chemotherapies: clarithromycin (Biaxin), lenalidomide (Revlimid) and dexamethasone (Decadron), for newly diagnosed multiple myeloma (MM). The main outcome that will be measured is survival without cancer worsening. This trial will take place in New York, the U.S....
Read More
